2013-02-08 08:12:16 -

KVISTGAARD, Denmark - February 8, 2013 - Bavarian Nordic A/S (OMX: BAVA)
announced today that it has appointed James B. Breitmeyer, M.D., Ph.D. to the
position of Executive Vice President and Division President of its Cancer
Vaccine division.

"We are pleased to welcome Dr. Breitmeyer to our executive management team,"
commented Anders Hedegaard, President and CEO of Bavarian Nordic. "We believe
that his long executive career in the pharmaceutical industry combined with his
solid oncology expertise will provide the perfect leadership for our cancer
vaccine division. He will apply more than two decades of clinical development
experience from research through commercialization to the advancement of our
cancer immunotherapy candidates, in particular PROSTVAC®, which is currently in
Phase 3 development."

"I am very enthusiastic about joining Bavarian Nordic at this exciting time,"
said James   B. Breitmeyer, M.D., Ph.D. "Immunotherapy of cancer is a career-long
interest of mine, and I believe PROSTVAC® represents a state-of-the art
approach, and a potentially improved treatment for patients suffering from
advanced prostate cancer. I am looking forward to leading the development of
this promising product candidate successfully through Phase 3 on its path
towards commercialization."

Dr. Breitmeyer served as Executive Vice President of Development and Chief
Medical Officer of Cadence Pharmaceuticals Inc. from 2006 to 2012. From 2001 to
2006, he served as Chief Medical Officer of Applied Molecular Evolution Inc., a
wholly-owned subsidiary of Eli Lilly and Co. From 2000 to 2001, Dr. Breitmeyer
served as President and Chief Executive Officer of the Harvard Clinical Research
Institute. From 1991 to 2000, he held a variety of positions at Serono
Laboratories Inc., including Chief Medical Officer and Senior Vice President of
Research and Development. Prior to Serono, he served as a scientific advisor to
Immunogen Inc., and held clinical and teaching positions at the Dana Farber
Cancer Institute and Harvard Medical School.

Dr. Breitmeyer received his M.D. and Ph.D. from Washington University School of
Medicine, is board certified in Internal Medicine and Oncology and is the author
or co-author of numerous publications.


Asger Aamund
Chairman of the Board


Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVAC®, a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial
and is being developed under a collaboration agreement with the National Cancer
Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in
nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNE®, a non-replicating smallpox vaccine candidate that is being developed
and supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. For more information, visit www.bavarian-
nordic.com

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.


201303uk: 
 hugin.info/100065/R/1676599/546505.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1676599]